AstraZeneca pays 660% premium for gene therapy firm LogicBio

(marketscreener.com) Shares of LogicBio Therapeuticsskyrocketed on Monday after Britain's AstraZeneca'ssaid it would buy the U.S.-based gene therapy developerat a rare 660% premium for $68 million. LoigBio's shares, which have traded below $1 since February,were up 637% at $2 before the bell, close to AstraZeneca's offerprice of $2.07 per share. ...https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/AstraZeneca-pays-660-premium-for-gene-therapy-firm-LogicBio-41914390/?utm_medium=RSS&utm_content=20221003